Top in rheumatology: Psoriatic arthritis guidance; cancer survival in autoimmune disease
Click Here to Manage Email Alerts
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis has updated its 2015 treatment recommendations of psoriatic arthritis to include the most up-to-date information.
The guideline authors approved seven overarching principles, and their position statements fell into groups relating to biosimilars and tapering therapies. A review of the guidance was the top story in rheumatology last week.
Another top story covered a study that found patients with preexisting autoimmune disease who were receiving immune checkpoint inhibitors for stage 3 or 4 melanoma had better 2-year survival than those without autoimmune disease.
Read these and more top stories in rheumatology below:
Patients may consider tapering once psoriatic arthritis treatment goals are reached
Patients with psoriatic arthritis may consider tapering once treatment goals are reached, according to guidance from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis published in Nature Reviews Rheumatology. Read more.
Patients with autoimmune disease receiving ICI exhibit better survival vs. controls
Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data. Read more.
Leflunomide noninferior to azathioprine as lupus nephritis maintenance therapy
Leflunomide is noninferior to azathioprine in terms of safety and efficacy for lupus nephritis maintenance therapy, according to data published in the Annals of the Rheumatic Diseases. Read more.
Higher quality of care fails to improve quality of life in lupus
Patients with systemic lupus erythematosus who report a high quality of care do not necessarily report meaningful clinical differences in quality of life, according to data published in Arthritis Care & Research. Read more.
Ustekinumab fails to show superiority to placebo in lupus
Stelara (ustekinumab; Janssen) failed to demonstrate superiority to placebo among patients with active systemic lupus erythematosus, according to phase-3 data published in Annals of the Rheumatic Diseases. Read more.